PMS19 Treatment Modifications and Costs of Biologic Therapy In Patients With Ankylosing Spondylitis  by Palmer, J.B. et al.
A156  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  
1540.59 days). CONCLUSIONS: Higher age and having arthroplasty were associated 
with increased risk of secondary hip fracture in elderly women. The higher risk of 
secondary hip fracture in patients with hip arthroplasty could be explained by their 
longer survival after primary treatment. Further analyses of risk factors are needed 
to elaborate effective prevention strategies for secondary hip fractures.
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OBJECTIVES: Bone loss is a common problem occurring among human immunode-
ficiency virus (HIV)-positive patients. Explanations for the bone loss are unknown. 
We estimated the prevalence of osteopenia among HIV-positive adults ages 18-49 
versus matched HIV-negative adults; and ranked predictors for osteopenia in terms 
of their contribution to a prediction model. METHODS: We conducted a cross-sec-
tional study on the 2005-2010 National Health and Nutrition Examination Survey 
(NHANES). HIV-positive individuals were identified according to HIV antibody test. 
Bone mineral density (BMD) T-score of femur neck was calculated based on the mean 
and SD from data for non-Hispanic white females ages 20-29 from the NHANES III. 
Osteopenia was defined as T-score between -1 and -2.5; osteoporosis was defined 
as T-score less than -2.5. A HIV-positive adult was matched with 3 HIV-negative 
adults at the same sex, age category and race. We used multiple logistic regression 
identified predictors of osteopenia among the matched cohort. RESULTS: 52 HIV-
positive individuals were identified. In the matched cohort 46 HIV-positive and 
138 HIV-negative adults were included. The mean age of the matched cohort was 
39.3±9.0 years, and 76.1% were male. No osteoporosis was observed in either case 
group or control group. The prevalence of osteopenia was 7.3% versus 1.7% among 
the cases compared to controls. Osteopenia occurred only among males in the cases 
and females in the controls. Alcohol consumption (p< 0.0001) was the strongest 
predictor of osteopenia, followed by activity intensity (p= 0.0003), family history of 
osteoporosis (p= 0.0007), and HIV itself (p= 0.0026), after controlling BMI and smoking 
status. CONCLUSIONS: HIV itself is a significant predictor for osteopenia; but due 
to lack of information on treatment history, it remains unclear if HIV medicine or 
treatment duration can increase the risk of osteopenia.
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OBJECTIVES: The risk of subsequent hip fracture is increased in presence of previous 
hip fracture. The most of the secondary hip fractures occur within the first 3 years 
after the initial hip fracture. The aim of our nationwide retrospective observational 
cohort study was to reveal the significance of demographic and clinical factors on 
time until subsequent hip fracture. METHODS: Patients aged 60 and over treated 
with primary femoral neck fractures in the year 2000 and suffered from contralateral 
hip fracture between 01 January 2000 and 31 December 2008 were selected from the 
database of the Hungarian National Health Insurance Fund. Patients’ data concern-
ing their age, gender, place of living, type of primary fracture, comorbid medical 
diseases, surgical intervention for primary fracture and hospital providing treatment 
for primary hip fracture were evaluated. Multinominal logistic regression were used 
to analyse associations between prognostic factors and the time (< 12 months, 12-24 
months, 24-36 months, 36-48 months, 48-60 months, > 60 months) until secondary 
fracture. RESULTS: 312 patients met the criteria. Having osteosynthesis as surgical 
intervention for primary fracture (osteosynthesis vs. arthroplsty, HR: 6.11, p= 0.02, 
CI: 1.28- 29.17) was significantly associated with a greater likelihood of suffering 
from secondary fracture in the fifth year than in the first year. Patients between 
60 and 69 years (60-69 years vs. > 90 years, HR: 20.95, p= 0.010, CI: 2.09- 209.44) were 
significantly more likely to have contralateral fracture in the sixth year than in the 
first year. CONCLUSIONS: First, we provide evidence of the influence of higher 
age and osteosynthesis as surgical intervention for primary fracture on the time 
until subsequent hip fractures in elderly Hungarian population. The results may 
help establish an effective strategy for the prevention of secondary hip fractures.
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OBJECTIVES: Approximately 10% of the US population is diagnosed with knee 
osteoarthritis by age 60. Disability due to arthritis increases health care costs and 
the risk of hospitalization, institutionalization, and mortality. Decreasing seden-
tary behavior can improve function and may be a modality for improving quality 
adjusted life years (QALYs). The purpose of this study was to investigate whether 
varying levels of sedentary behavior impacts the QALY differently. METHODS: This 
study used longitudinal data from the accelerometer study of the Osteoarthritis 
Initiative (OAI) collected at baseline (OAI 48-month visit) and 2-year follow-up 
(OAI 72-month visit). We restricted analyses to participants with 4-7 valid days 
of accelerometer monitoring and individuals with complete health utility data, 
yielding a sample of 1794 community dwelling adults with or at risk for radio-
graphic knee OA. QALYs (SF6D) were calculated at 48 and 72 months. Participants 
were classified into quartiles based on average daily sedentary time (most seden-
tary Q1 > = 11.6, 10.7< = Q2< 11.6, 9.7< = Q3< 10.7, least sedentary Q4< 9.7 hours). The 
association between sedentary behavior and QALYs was examined using median 
regression adjusting for age, gender, BMI. RESULTS: Average(SD) QALYs over the 
2-year follow-up were 1.56(0.23), 1.61(0.20), 1.60(0.23), 1.60(0.23) for Q1-Q4 respec-
PMS19
treatMent ModIfIcatIonS and coStS of BIologIc tHeraPy In PatIentS 
WItH ankyloSIng SPondylItIS
Palmer J.B.1, Li Y.1, Herrera V.1, Tsang Y.1, Liao M.2, Ozturk Z.1
1Novartis Pharmaceuticals, East Hanover, NJ, USA, 2KMK Consulting Inc., Florham Park, NJ, USA
OBJECTIVES: Limited information exists on real-world use of biologic agents in 
ankylosing spondylitis (AS). This study evaluated the treatment patterns and costs 
of biologic therapy and disease-modifying antirheumatic drugs (DMARDs) in AS 
patients. METHODS: MarketScan claims databases were used to identify biolog-
ics treatment-naïve AS patients (≥ 18 years of age with no biologics in the past 
6 months) who initiated biologic treatment between 10/1/2009 and 09/30/2010. 
Frequency of biologic switching, duration, modification of treatment, and medical 
and pharmacy drug costs for each line of biologic therapy was analyzed during the 
3-year follow-up. RESULTS: A cohort of 339 AS patients was identified. First-line bio-
logics were: etanercept (n= 140), adalimumab (n= 137), infliximab (n= 41), golimumab 
(n= 18) and certolizumab pegol (n= 3). Approximately two-thirds of the patients 
(64.6%) discontinued their first-line biologic therapy and did not restart any biologi-
cal therapy, 23.6% of patients stayed on their first-line, 8.8% switched to second-line 
and 2.9% to third-line therapies. Patients who switched to a second- or third-line 
biologic treatment remained on their first-line agent for less time (336, 325-days, 
respectively) than those who did not switch (502-days). Most common treatment 
modifications in first-line were DMARD add-on (6.5%) and removal (5.6%). Time to 
first treatment-modification was shorter for those who switched to second- (88 
days) and third-line therapy (6-days) vs. those who remained on first-line (160-days). 
Monthly-per-member medical costs were greatest for non-switchers ($363) than for 
patients who received second-($249) or third-line ($113) treatment. Monthly-per-
member overall pharmacy drug costs were similar for patients with first-($1,908), 
second-($1,955) or third-line and above ($1,890) therapy. CONCLUSIONS: Sixty 
five percent of AS patients discontinued their first-line agent during the follow-up 
period. Those who switched biologics had more modifications to their treatment. 
Patients who switched to second- or third-line biologics had lower medical costs; 
however, their pharmacy costs were similar to those who continued their first-line.
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OBJECTIVES: Information is limited regarding the interim and long-term outcomes 
associated with knee microfracture surgery. The objective of the study was to describe 
failure rates 1 year, 3 years, and 5 years after knee microfracture surgery in an admin-
istrative claims database. METHODS: Beneficiaries with knee microfracture surgery 
between 10/1/2007 and 9/30/2008 (index surgery) and continuous enrollment 24 
months prior to the index surgery were identified in the Truven Health Marketscan® 
Commercial, Medicare Supplemental, and Medicaid databases. Patients with any knee 
procedures in the 2 years prior to index surgery were excluded. Patients were fol-
lowed for a minimum of 3 years after the index surgery and a subgroup of patients 
were followed for 5 years. Procedure failure was defined as receiving a total knee 
replacement (TKR) or revision, microfracture or autologous chondrocyte implantation 
subsequent to index surgery. RESULTS: A total of 3,498 patients (2,948 commercial 
payer, 351 Medicare and 199 Medicaid) met the study inclusion criteria. Failure rates 
increased with increasing years of follow-up: 9% within 1 year, 18% within 3 years, 
and 32% within 5 years. Among commercial payer patients, 8% were failures after 
1 year, compared to 16% after 3 years and 31% after 5 years. The highest rates of 
failure were observed among Medicare beneficiaries, in which 18%, 30%, and 41% of 
patients received knee procedures within 1 year, 3 years, and 5 years, respectively. 
Failure rates defined by TKR after microfracture surgery were 5% within 1 year, 12% 
within 3 years, and 22% within 5 years. CONCLUSIONS: Although the gold standard, 
knee microfracture surgeries have high failure rates as defined by repeat procedures 
within five years. There is a need for procedures that provide durable improvements 
in health outcomes and reduce the need for repeat interventions.
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OBJECTIVES: Hip fracture is most serious consequence of osteoporosis with sig-
nificant financial and personal costs. Our aim was to determine the significance 
of demographic and clinical factors for contralateral hip fracture among elderly 
women. METHODS: In our retrospective observational cohort study women aged 
60 years and over treated with primary femoral neck fractures in the year 2000 
were selected from the database of the Hungarian National Health Insurance Fund. 
Contralateral hip fractures were recorded between 01 January 2000 and 31 December 
2008. Patients’ data including age, place of living, hospital providing treatment for 
primary hip fracture, type of primary fracture, comorbidities, type of primary surgi-
cal intervention and survival time were studied. Prognostic factors of secondary hip 
fracture were evaluated using multivariate Cox proportional hazard regression and 
Kaplan-Meier survival analysis. RESULTS: 2866 subjects met the criteria. 263 patients 
(9.17%) suffered from secondary hip fracture during the observation period. The mean 
time until secondary fracture was 1142.82 days. Expressed as cases per person-years 
the incidence of subsequent hip fracture was 0.23. Significant correlations were found 
between higher age (years, HR: 1.03, p< 0.001, CI: 1.01- 1.05), having hip arthroplasty 
as type of surgical intervention for primary fracture (osteosynthesis vs. arthropl-
sty, HR: 1.63, p= 0.022, CI: 1.19- 2.24) and occurrence of subsequent hip fractures. 
Comparing patients’ survival on different surgical intervention, log rank test showed 
significantly longer survival (p= 0.027) in patients with arthroplasty (mean survival 
time: 1739.84 days) compared with those having osteosynthesis (mean survival time: 
